Description: Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd. in March 2009. Celltrion Healthcare Co., Ltd. was founded in 1999 and is headquartered in Incheon, South Korea.
Home Page: www.celltrionhealthcare.com
Office Building: 19
Incheon,
South Korea
Phone:
82 850 6400
Officers
| Name | Title |
|---|---|
| Joon Serk Seo | Exec. Chairman |
| Hyoung Ki Kim | CEO & Exec. Director |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Providers & Services |
| GIC Sub-Industry: | Health Care Distributors |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 4.4931 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 149 |